NEW CHOLESTEROL METABOLITIS DISULPHATE 5-CHOLESTEN-3β, 25-DIOL (25HCDS) FOR THERAPY OF SUBSTANCES EXCHANGE DISEASES, HYPERLIPIDEMIA, DIABETES, FATTY HOSPITAL AND AEROTUS

摘要

The 5-cholesten-3β, 25-diol (25HCDS) disulfate was found to be the original PPARγ agonist and LXR antagonist, used to treat lipid metabolism disorders and inflammatory diseases, including without limitation fatty liver disease, inflammatory bowel disease and atherosclerotic diseases .